The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose

European Journal of Clinical Pharmacology

Volumn 62, Issue 4, 2006, Pages 291-296

  Herman, Darja ^a   Locatelli, Igor ^b   Grabnar, Iztok ^b   Peternel, Polona ^c   Stegnar, Mojca ^c   Lainščak, Mitja ^d   Mrhar, Aleš ^b   Breskvar, Katja ^a   Dolžan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d General Hospital Murska Sobota   (Slovenia)

Author keywords

Anticoagulant therapy; Drug drug interaction; Warfarin pharmacokinetics

Indexed keywords

10 HYDROXYWARFARIN; 7 HYDROXYWARFARIN; AMIODARONE; CARBAMAZEPINE; CYTOCHROME P450 2C9; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; CALCULATION; CAUCASIAN; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AMIODARONE; ARYL HYDROCARBON HYDROXYLASES; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHARMACOKINETICS; WARFARIN;

EID: 33645679794     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0104-4     Document Type: Article

References (41)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:204S-233S
2. Gage BF, Fihn SD, White RH (2000) Management and dosing of warfarin therapy. Am J Med 109:481-488
3. Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
4. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V (2005) Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 5:193-202
5. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14:539-547
6. Hansen JM, Siersboek-Nielsen K, Skovsted L (1971) Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 12:539-543
7. Ross JR, Beeley L (1980) Interaction between carbamazepine and warfarin. Br Med J 208:1415-1416
8. Kendall AG, Boivin M (1981) Warfarin-carbamazepine interaction. Ann Intern Med 94:280
9. Massey EW (1983) Effect of carbamazepine on Coumadin metabolism. Ann Neurol 13:691-692
10. Denbow CE, Fraser HS (1990) Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 83:981
11. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969-1979
12. Martinowitz U, Rabinovich J, Goldfarb D, Many A, Bank H (1981) Interaction between warfarin sodium and amiodarone. N Engl J Med 304:671-672
13. Rees A, Dalal JJ, Reid PG, Henderson AH, Lewis MJ (1981) Dangers of amiodarone and anticoagulant treatment. Br Med J (Clin Res Ed) 282:1756-1757
14. Hamer A, Peter T, Mandel WJ, Scheinman MM, Weiss D (1982) The potentiation of warfarin anticoagulation by amiodarone. Circulation 65:1025-1029
15. Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M (1988) The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 148:1779-1781
16. Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U, Bank H (1985) Mechanism of warfarin potentiation by amiodarone: dose - and concentration - dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 28:257-261
17. Watt AH, Stephens MR, Buss DC, Routledge PA (1985) Amiodarone reduces plasma warfarin clearance in man. Br J Clin Pharmacol 20:707-709
18. O'Reilly RA, Trager WF, Rettie AE, Goulart DA (1987) Interaction of amiodarone with racemic warfarin and separated enantiomorphs in humans. Clin Pharmacol Ther 42:290-294
19. Cheung B, Lam FM, Kumana CR (1996) Insidiously evolving, occult drug interaction involving warfarin and amiodarone. BMJ 312:107-108
20. Sanoski CA, Bauman JL (2002) Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 121:19-23
21. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA, Goulart DA (1992) The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 51:398-407
22. Andrus MR (2004) Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 24:285-290
23. Gaw A, Wosornu D (1992) Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 340:979-980
24. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB (1999) The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 39:86-90
25. Hickmott H, Wynne H, Kamali F (2003) The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 89:949-950
26. http://www.theriaque.org/AnalyseOrdonnances/home.cfm (Date: 21st November 2005)
27. Yasar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631
28. Locatelli I, Kmetec V, Mrhar A, Grabnar I (2005) Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 818:191-198
29. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzales FJ, Idle JR (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5:389-392
30. Aithal GP, Say CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
31. Ogg MS, Brennan P, Meade T, Humphries SE (1999) CYP2C9*3 allelic variant and bleeding complications. Lancet 354:1124
32. Taube J, Halsall D, Baglin T (2000). Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin senstitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816-1819
33. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84:775-778
34. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG (2000) Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 128:281-285
35. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD (2002) The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 194:267-273
36. Higashi M, Veenstra DL, Midori Kondo L, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690-1698
37. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of cytochrome P450 CYP2C9 and 2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710
38. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75:204-212
39. D'Andrea G, D'ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M (2005) A polymorphism in VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649
40. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745-1751
41. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293